CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Seretide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00455923
NCT00455923Phase 4Completed
CompareCT.gov

SERETIDE vs FLIXOTIDE in Mild Persistent Asthma (GINAII)

GlaxoSmithKline·interventional·Posted Apr 4, 2007·Updated Feb 5, 2018

In Brief

A Phase 4 clinical trial evaluating Seretide and Flixotide for Asthma. Completed, enrolled 100 participants across 1 site.

Detailed Summary

An 18 months randomised double-blind study with two parallel arms with start dose of inhaled SERETIDE 50/100mcg BD or FLIXOTIDE 100mcg BD, Phase I is 6 months where the patient will be up-titrated until well controlled is achieved, After 6 months the treatment continues without changes during 9 months = PhaseII. The aim is to investigate and evaluate the assumption that the combination therapy with SERETIDE controls mild persistent asthma better than inhaled corticosteroids(FLIXOTIDE) alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesSweden
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 4, 2007
Enrollment StartMay 3, 2005
Primary CompletionJul 31, 2007
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.2 years ago

Interventions

Seretidedrug

Seretide

Flixotidedrug

Flixotide